Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $156.40 | Total: $782.00 |
| 1 | 10 | $132.48 | Total: $1,324.80 |
| 1 | 25 | $112.24 | Total: $2,806.00 |
| 1 | 50 | $95.68 | Total: $4,784.00 |
| 1 | 100 | $82.80 | Total: $8,280.00 |
Overview
Ramucirumab, a human VEGFR-2 antagonist, is used for the treatment of solid tumors.
Chemical Properties
| Molecular Formula | C285H434N74O88S2 |
| Molecular Weight | 147 kDa |
| CAS Numbers | 947687-13-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
Storage and Handling
0C Short Term, -20C Long Term
References
Fala L. Cyramza [Ramucirumab] Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8[Spec Feature] 49-53.